Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-blind, Randomized, Parallel, Multiple-center Study to Compare the Efficacy and Safety of 1PC002 and Atorvastatin in Taiwanese Patients With Hypercholesterolemia

NCT01710007 is registered in ClinicalTrials.gov with Orient Pharma Co., Ltd. as lead sponsor.

NCT NCT01710007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01710007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-blind, Randomized, Parallel, Multiple-center Study to Compare the Efficacy and Safety of 1PC002 and Atorvastatin in Taiwanese Patients With Hypercholesterolemia
Lead sponsor
Orient Pharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2012
Enrollment
202 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia